

# Long-term sequelae of COVID-19 Post-acute COVID syndrome

#### Steven Deeks, MD

Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General University of California, San Francisco







# Reports of post-acute symptoms emerged in the media early in the pandemic



# The emerging long-term complications of Covid-19, explained

"It is a true roller coaster of symptoms and severities, with each new day offering many unknowns."

By Lois Parshley | May 8, 2020, 1:10pm EDT



From 'brain fog' to heart damage, COVID-19's lingering problems alarm scientists

By Jennifer Couzin-Frankel | Jul. 31, 2020, 1:30 PM

# The New York Times

#### Surviving Covid-19 May Not Feel Like Recovery for Some

Debilitating symptoms can last long after a person's body has gotten rid of the coronavirus, a reality Italians are now confronting.



PRESS PLAY WITH MADELEINE BRAND

## Think COVID-19 lasts 2 weeks? This patient has been suffering for months


Hosted by Madeleine Brand • Jul. 24, 2020 CORONAVIRUS



#### CORONAVIRUS

#### Rapid implementation of mobile technology for real-time epidemiology of COVID-19

David A. Drew<sup>1.\*</sup>, Long H. Nguyen<sup>1.\*</sup>, Claire J. Steves<sup>2.3</sup>, Cristina Menni<sup>2</sup>, Maxim Freydin<sup>2</sup>, Thomas Varsavsky<sup>4</sup>, Carole H. Sudre<sup>4</sup>, M. Jorge Cardoso<sup>4</sup>, Sebastien Ourselin<sup>4</sup>, Jonathan Wolf<sup>5</sup>, Tim D. Spector<sup>2.5</sup>+, Andrew T. Chan<sup>1.6</sup>+±, COPE Consortium§



- The COVID Symptom Study uses an app into which over 4 million of people in the US, UK and Sweden have entered their symptoms
- 4182 incident cases (all selfdescribed as "normal" prior to infection)
  - Symptoms > 4 weeks: 13.3%
  - Symptoms > 8 weeks: 4.5%
  - Symptoms > 12 weeks: 2.3%



Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App


Science

CORONAVIRUS

#### Rapid implementation of mobile technology for real-time epidemiology of COVID-19

David A. Drew<sup>1</sup>\*, Long H. Nguyen<sup>1</sup>\*, Claire J. Steves<sup>2,3</sup>, Cristina Menni<sup>2</sup>, Maxim Freydin<sup>2</sup>, Thomas Varsavsky<sup>4</sup>, Carole H. Sudre<sup>4</sup>, M. Jorge Cardoso<sup>4</sup>, Sebastien Ourselin<sup>4</sup>, Jonathan Wolf<sup>5</sup>, Tim D. Spector<sup>2,5</sup>+, Andrew T. Chan<sup>1,6</sup>+±. COPE Consortium§





Comparator group: Age 20-30

- Predictors of long-COVID (> 28 days)
   versus transient disease (< 10 days)</li>
  - Sex (female)
  - Age
  - Symptomatic acute infection (> 5 sx): OR 3.53
  - BMI
- Free text: late delay of cardiac and neurologic symptoms

## What are the long-term sequelae?

#### $medR\chi iv$

Symptom clusters in Covid 19:A potential clinical prediction tool from the COVID Symptom study app

© Carole H Sudre, Karla Lee, Mary Ni Lochlainn, Thomas Varsavsky, Benjamin Murray, Mark S. Graham, © Cristina Menni, Marc Modat, Ruth C.E. Bowyer, Long H Nguyen, David Alden Drew, Amit D Joshi, Wenjie Ma, Chuan Guo Guo, Chun Han Lo, Sajaysurya Ganesh, Abubakar Buwe, Joan Capdevila Pujol, Julien Lavigne du Cadet, Alessia Visconti, © Maxim Freydin, Julia S. El Sayed Moustafa, Mario Falchi, Richard Davies, Maria F. Gomez, Tove Fall, M. Jorge Cardoso, Jonathan Wolf, Paul W Franks, Andrew T Chan, Timothy D Spector, Claire J Steves, Sebastien Ourselin

# The COVID Symptom Study Six Emerging Clusters

- 1. ('flu-like' with no fever): Headache, loss of smell, muscle pains, cough, sore throat, chest pain, no fever
- 2. ('flu-like' with fever): Headache, loss of smell, cough, sore throat, hoarseness, fever, loss of appetite
- 3. (gastrointestinal): Headache, loss of smell, loss of appetite, diarrhea, sore throat, chest pain, no cough
- 4. (severe level one, fatigue): Headache, loss of smell, cough, fever, hoarseness, chest pain, fatigue
- 5. (severe level two, confusion): Headache, loss of smell, loss of appetite, cough, fever, hoarseness, sore throat, chest pain, fatigue, confusion, muscle pain
- 6. (severe level three, abdominal and respiratory): Headache, loss of smell, loss of appetite, cough, fever, hoarseness, sore throat, chest pain, fatigue, confusion, muscle pain, shortness of breath, diarrhea, abdominal pain



#### Neurologic

Headaches
Dizziness
Encephalopathy
Guillain-Barré
Ageusia
Myalgia
Anosmia
Stroke

#### Renal


Acute kidney injury Proteinuria Hematuria

#### Hepatic

Elevated aminotransferases Elevated bilirubin

#### Gastrointestinal

Diarrhea
Nausea/vomiting
Abdominal pain
Anorexia



#### medicine

#### **Extrapulmonary manifestations of COVID-19**

Aakriti Gupta 12.3.2°, Mahesh V. Madhavan 12.2°, Kartik Sehgal 45.6.2°, Nandini Nair', Shiwani Mahajan 38, Tejasav S. Sehrawat 79, Behnood Bikdeli 3.3, Neha Ahluwalia 79, John C. Ausiello', Elaine Y. Wan', Daniel E. Freedberg'i, Ajay J. Kirtane', Sahii A. Parikh'2, Mathew S. Maurer', Anna S. Nordvigi'2, Domenico Accili'7, Joan M. Bathon'13, Sumit Mohan 13.15, Kenneth A. Bauer 6, Martin B. Leon'12, Harlan M. Krumholz 13.16, Nir Uriel', Mandeep R. Mehra'7, Mitchell S. V. Elkind 12.15, Gregg W. Stone 18, Jan Schwartz', David D. Ho'7, John P. Bilezikian' and Donald W. Landry 14.25

#### JAMA Cardiology | Original Investigation

#### Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Valentina O. Puntmann, MD, PhD; M. Ludovica Carerj, MD; Imke Wieters, MD; Masia Fahim; Christophe Arendt, MD; Jedrzej Hoffmann, MD; Anastasia Shchendrygina, MD, PhD; Felicitas Escher, MD; Mariuca Vasa-Nicotera, MD; Andreas M. Zeiher, MD; Maria Vehreschild, MD; Eike Nagel, MD

JAMA Cardiology | Brief Report

#### Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Diana Lindner, PhD; Antonia Fitzek, MD; Hanna Bräuninger, MS; Ganna Aleshcheva, PhD; Caroline Edler, MD; Kira Meissner; Katharina Scherschel, PhD; Paulus Kirchhof, MD; Felicitas Escher, MD; Heinz-Peter Schultheiss, MD; Stefan Blankenberg, MD; Klaus Püschel, MD; Dirk Westermann, MD



#### Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

#### The New Hork Times

Opinion

## Covid-19 Is Creating a Wave of Heart Disease

Emerging data show that some of the coronavirus's most potent damage is inflicted on the heart.

**By Haider Warraich**Dr. Warraich is a cardiologist


- Recent "severe" infection (n=100, median 71 days post-recovery): Most (78%) had abnormal cardiac MR findings, including active myocarditis (60%) and tissue damage (fibrosis)
- Endomyocardial biopsy: Active lymphocytic inflammation
- Autopsy study: Viral RNA in cardiomyocytes
- Myocarditis reported in 15% of college athletes (many with mild/asymptomatic disease)

## Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

Cristina Basso (1) 1, Ornella Leone (2) 2, Stefania Rizzo (1) 1, Monica De Gaspari 1, Allard C. van der Wal 3, Marie-Christine Aubry 4, Melanie C. Bois (1) 4, Peter T. Lin (1) 4, Joseph J. Maleszewski (1) 4, and James R. Stone (1) 5\*

The significance of COVID-19-associated myocardial injury: how overinterpretation of scientific findings can fuel media sensationalism and spread misinformation

Nikolaos G. Frangogiannis @ \*




Autopsy study (n=21): Macrophage infiltration common, myocarditis/thombi rare

Myocardial injury (troponin leak) common (10-45% of cases)

Most cardiovascular harm may be related to supply/demand, in contrast to early reports that SARS-CoV-2 infection "ravages the heart"

Long-term impact of COVID on heart is unknown

### **Pulmonary sequelae**



Lung scans from a 50-year-old show that damage from COVID-19 (red) can improve with time — but many patients have lasting symptoms

- Symptoms/signs of restrictive lung disease common among those who had been hospitalized
  - 30d = 53% decreased DLCO, 49% diminished respiratory muscle strength
  - 3mo = 25% decreased DLCO
  - 3mo = 71% with radiographic evidence of interstitial thickening and fibrosis

#### **COVID-19** and the brain

- Severe COVID-19 infection triggers a complex inflammatory response that may result in cytokine storm syndrome, stroke, hypoxia, and/or delirium (Cohran et al, Brain Behav Imm)
- Past pandemics have demonstrated that diverse types of neuropsychiatric symptoms, such as encephalopathy, mood changes, psychosis, neuromuscular dysfunction, or demyelinating processes, may accompany acute viral infection, or may follow infection by weeks, months, or longer in recovered patients

#### Does COVID-19 cause diabetes?

- Diabetes is associated with an increased risk of severe COVID-19
- Incident diabetes mellitus (DKA, hyperosmolar coma) and acute worsening variably reported to be common in those with acute infection
- ACE2 receptor are present on pancreatic islet cells, adipose tissue and the small intestine
- Is there a "diabetogenic" effect of COVID-19?
  - CoviDIAB Registry: covidiab.e-dendrite.com

# What are the putative mechanisms that might contribute to this syndrome?

#### JAMA Cardiology | Original Investigation

#### Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Diana Lindner, PhD<sup>1,2</sup>: Antonia Fitzek, MD<sup>3</sup>: Hanna Bräuninger, MS<sup>1,2</sup>: et al.



Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients


Myriam Remmelink, Ricardo De Mendonça, Nicky D'Haene, Sarah De Clercg, Camille Verocg, Laetitia Lebrun, Philomène



**Neuroinvasion of SARS-CoV-2 in human and mouse brain** 

Song E, ... Iwasaki A. 2020.

Viral RNA can be detected in autopsy tissues weeks after acute infection






## Longitudinal analyses reveal immunological misfiring in severe COVID-19

https://doi.org/10.1038/s41586-020-2588-y

Received: 23 June 2020

Accepted: 21 July 2020

Published online: 27 July 2020



Carolina Lucas<sup>1,17</sup>, Patrick Wong<sup>1,17</sup>, Jon Klein<sup>1,17</sup>, Tiago B. R. Castro<sup>2,17</sup>, Julio Silva<sup>1</sup>, Maria Sundaram<sup>3</sup>, Mallory K. Ellingson<sup>3</sup>, Tianyang Mao<sup>1</sup>, Ji Eun Oh<sup>1</sup>, Benjamin Israelow<sup>1,4</sup>, Takehiro Takahashi<sup>1</sup>, Maria Tokuyama<sup>1</sup>, Peiwen Lu<sup>1</sup>, Arvind Venkataraman<sup>1</sup>, Annsea Park<sup>1</sup>, Subhasis Mohanty<sup>4</sup>, Haowei Wang<sup>4</sup>, Anne L. Wyllie<sup>3</sup>, Chantal B. F. Vogels<sup>3</sup>, Rebecca Earnest<sup>3</sup>, Sarah Lapidus<sup>3</sup>, Isabel M. Ott<sup>3</sup>, Adam J. Moore<sup>3</sup>, M. Catherine Muenker<sup>3</sup>, John B. Fournier<sup>4</sup>, Melissa Campbell<sup>4</sup>, Camila D. Odio<sup>4</sup>, Arnau Casanovas-Massana<sup>3</sup>, Yale IMPACT Team<sup>\*</sup>, Roy Herbst<sup>5</sup>, Albert C. Shaw<sup>4</sup>, Ruslan Medzhitov<sup>1,6</sup>, Wade L. Schulz<sup>7,8</sup>, Nathan D. Grubaugh<sup>3</sup>, Charles Dela Cruz<sup>9</sup>, Shelli Farhadian<sup>4</sup>, Albert I. Ko<sup>3,4</sup>, Saad B. Omer<sup>3,4,10</sup> & Akiko Iwasaki<sup>1,6</sup>

## Sex differences in immune responses that underlie COVID-19 disease outcomes

https://doi.org/10.1038/s41586-020-2700-3

Received: 4 June 2020

Accepted: 19 August 2020

Published online: 26 August 2020

Check for updates

Takehiro Takahashi<sup>1,21</sup>, Mallory K. Ellingson<sup>2,21</sup>, Patrick Wong<sup>1,21</sup>, Benjamin Israelow<sup>1,3,21</sup>, Carolina Lucas<sup>1,21</sup>, Jon Klein<sup>1,21</sup>, Julio Silva<sup>1,21</sup>, Tianyang Mao<sup>1,21</sup>, Ji Eun Oh<sup>1</sup>, Maria Tokuyama<sup>1</sup>, Peiwen Lu<sup>1</sup>, Arvind Venkataraman<sup>1</sup>, Annsea Park<sup>1</sup>, Feimei Liu<sup>1,4</sup>, Amit Meir<sup>5</sup>, Jonathan Sun<sup>6</sup>, Eric Y. Wang<sup>1</sup>, Arnau Casanovas-Massana<sup>2</sup>, Anne L. Wyllie<sup>2</sup>, Chantal B. F. Vogels<sup>2</sup>, Rebecca Earnest<sup>2</sup>, Sarah Lapidus<sup>2</sup>, Isabel M. Ott<sup>2,7</sup>, Adam J. Moore<sup>2</sup>, Yale IMPACT Research Team\*, Albert Shaw<sup>3</sup>, John B. Fournier<sup>3</sup>, Camila D. Odio<sup>3</sup>, Shelli Farhadian<sup>3</sup>, Charles Dela Cruz<sup>8</sup>, Nathan D. Grubaugh<sup>2</sup>, Wade L. Schulz<sup>9,10</sup>, Aaron M. Ring<sup>1</sup>, Albert I. Ko<sup>2</sup>, Saad B. Omer<sup>2,3,11,12</sup> & Akiko Iwasaki<sup>1,13</sup>

## **Endothelial injury**




Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

George Goshua\*, Alexander B Pine\*, Matthew L Meizlish\*, C-Hong Chang, Hanming Zhang, Parveen Bahel, Audrey Baluha, Noffar Bar, Robert D Bona, Adrienne J Burns, Charles S Dela Cruz, Anne Dumont, Stephanie Halene, John Hwa, Jonathan Koff, Hope Menninger, Natalia Neparidze, Christina Price, Jonathan M Siner, Christopher Tormey, Henry M Rinder, Hyung J Chun\*, Alfred I Lee\*

- Endothelium: single cell layer of cells that covers pro-thrombotic connective tissue
  - ACE2 levels high on endothelial cells
- Vicious circle of injury and reaction leading to microvascular thrombosis
  - Pre-existing disease: diabetes, hypertension and other common COVID risk factors
  - Direct infection: target for SARS-CoV-2 infection
  - Inflammation: release of multiple pro-coagulant factors (VWF, others)
- Consequences: small vessel ischemia (digit necrosis), strokes, cardiovascular events

# Dysautonamia (autonomic nervous system dysfunction) might explain multiple symptoms




# How should these compilcations be managed?



#### Coronavirus Disease 2019 and the Athletic Heart Emerging Perspectives on Pathology, Risks, and Return to Play

Jonathan H. Kim, MD, MSc; Benjamin D. Levine, MD; Dermot Phelan, MD, PhD; Michael S. Emery, MD, MS; Mathew W. Martinez, MD; Eugene H. Chung, MD, MSc; Paul D. Thompson, MD; Aaron L. Baggish, MD






Return to Play for Athletes After Coronavirus Disease 2019 Infection— Making High-Stakes Recommendations as Data Evolve

James E. Udelson, MD; Michael A. Curtis, MEd, CSCS; Ethan J. Rowin, MD

- Complex algorithms published for high school athletes, adult engaged in recreational sports, and professional athletes
- Slow escalation of activity recommended for those with mild COVID and no CV symptoms
- Aggressive work-up (ECG, troponins, echocardiogram) for those with CV symptoms (particularly syncope), progressing to CMR as needed





#### PRACTICE POINTER

#### Management of post-acute covid-19 in primary care

Trisha Greenhalgh, <sup>1</sup> Matthew Knight, <sup>2</sup> Christine A'Court, <sup>1</sup> Maria Buxton, <sup>3</sup> Laiba Husain<sup>1</sup>

The establishment of one-stop clinics that address the the multisystem nature of COVID-19 are emerging, providing patients with access to support and potentially treatment, as well as becoming a critical infrastructure for understanding the nature of this syndrome

#### Planning for the Post-COVID Syndrome: How Payers Can Mitigate Long-Term Complications of the Pandemic

David H. Jiang, B.A. 1 and Rozalina G. McCoy, M.D., M.S. 1,2

# Long-term Sequelae of COVID-19 Post-COVID syndrome, long COVID, long haulers

- Limited peer-reviewed data focused on the occurrence or prevalence of COVID-19—related long-term sequelae
  - Most of the agenda driven by anecdotes and media stories
  - Publication bias likely real
- Reasonable to anticipate manifestations based on established knowledge of SARS-CoV-2 pathophysiology, other acute viral infection outcomes
  - Entry receptor ACE2 expressed across extrapulmonary tissue
  - Inflammation
  - Hypercoagulability and clotting
- Among patients recovering from severe SARS-CoV or MERS-CoV infection, long-term complications were not uncommon
- Although there was initial skepticism, the consensus now seems to be that this is real and will need to be addressed